The Oncology Institute Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of The Oncology Institute Inc (TOI) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: The Oncology Institute Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 587M vs 608,917M combined for its competitors (0.1% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+9.9% annualized vs trailing 12 months), vs holding steady (+1.3%) for its tracked peer group.
- Growth: The Oncology Institute Inc generated 34.6% revenue growth year over year in Q2 2026, vs -24.7% for its competitors combined.
- Profitability: Its -5.1% net margin compares with 2.2% for the peer group.
- Peer revenue share: The Oncology Institute Inc accounted for 0.1% of combined revenue among its tracked peer group, up from 0.1% a year earlier.
- Peer differentiation: Revenue per employee of $0.92M compares with $2.10M for the peer group (0.4x).
- Structure: The Oncology Institute Inc operates in the following segments: Specialty Pharmacy,, Patient Services,, Clinical Trials and Other,.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
TOI Sales vs. its Competitors, Q2 2026
The Oncology Institute Inc reported revenue growth of 34.62 % year on year in Q2 2026, above its competitors' combined revenue change of -24.71 %.
With a net margin of -5.11 %, The Oncology Institute Inc reported lower profitability than its competitors (2.16 %).
The Oncology Institute Inc generated 0.10 % of the combined sales of its peer group, up from 0.06 % a year earlier.
API endpoints for this dataset
The Oncology Institute Inc vs. its Competitors, Q2 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in The Oncology Institute Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across The Oncology Institute Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| The Oncology Institute Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (1) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (1) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across The Oncology Institute Inc's competitor groups requires a Commercial License.
For context: the Healthcare Facilities industry grew revenue 14.7% year over year, combined, vs 34.6% for The Oncology Institute Inc. The Oncology Institute Inc's share of combined industry revenue moved from 0.11% to 0.13%, a gain of 0.02 percentage points.
The Oncology Institute Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| The Oncology Institute Inc | No | Yes | Yes | No |
| Competitors combined (8) | ||||
| High-Confidence Competitors (4) | ||||
| Similar Growth & Profitability (8) | 62.50 % (5 of 8) | 100.00 % (8 of 8) | 87.50 % (7 of 8) | 37.50 % (3 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
TOI Stock Performance relative to its Competitors
TOI Stock Performance relative to High-Confidence Competitors
TOI Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Merck and Co Inc | 282.9% | Outperformed |
| 2 | Cardinal Health Inc | 282.9% | Outperformed |
| 3 | Bristol myers Squibb Company | 282.9% | Outperformed |
| 4 | Mckesson Corporation | 282.9% | Outperformed |
| 5 | Pfizer Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for The Oncology Institute Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
The Oncology Institute Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of The Oncology Institute Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 The Oncology Institute Inc |
637.76 | 587.24 |
 Merck and Co Inc |
364,337.35 | 66,569.00 |
 Astrazeneca Plc |
292,531.36 | 58,739.00 |
 Pfizer Inc |
167,957.96 | 63,625.00 |
 Bristol myers Squibb Company |
127,973.76 | 50,033.00 |
 Mckesson Corporation |
126,274.52 | 410,983.00 |
| SUBTOTAL | 1,214,763.30 | 926,398.10 |
Sign in to see all competitors of The Oncology Institute Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on The Oncology Institute Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
The Oncology Institute Inc's Competitors Named by the Company
Competitive relationships identified from The Oncology Institute Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| American Oncology Network, Inc. | Company report | 85% |
| Magellan Health | Company report | 85% |
| OneOncology, Inc. | Company report | 85% |
| OncoHealth | Company report | 85% |
| Thyme Care | Company report | 85% |
| Evolent Health | Company report | 85% |
| U.S. Oncology Network, Inc. | Company report | 85% |
| Florida Cancer Specialists & Research Institute, LLC | Company report | 85% |
| eviCore Healthcare | Company report | 85% |
| AIM Specialty Health | Company report | 85% |
| New Century Health | Company report | 85% |
| One Oncology | Company report | 85% |
| Deerfield Funds | Company report | 85% |
| Deerfield Management | Company report | 85% |
Company report basis, confidence, active dates and source counts for The Oncology Institute Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
The Oncology Institute Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| The Oncology Institute Inc | Specialty Pharmacy, 64.38 % |
| Merck and Co Inc | Pharmaceutical segment 89.95 % |
| Pfizer Inc | U.S. Commercial Division 58.35 % |
| Mckesson Corporation | North American Pharmaceutical 82.34 % |
| Aon Plc | Risk Capital 65.40 % |
| Cardinal Health Inc | Pharmaceutical and Specialty Solutions 92.08 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
The Oncology Institute Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| The Oncology Institute Inc | 638 | 916,137 | -42,222 |
| Merck and Co Inc | 364,337 | 887,587 | 42,267 |
| Astrazeneca Plc | 292,531 | 706,847 | 123,141 |
| Pfizer Inc | 167,958 | 848,333 | 54,160 |
| Bristol myers Squibb Company | 127,974 | 1,539,477 | 284,338 |
| Mckesson Corporation | 126,275 | 8,058,490 | 103,922 |
| PEERS TOTAL | 1,214,126 | 2,101,727 | 85,804 |
Sign in to see all peers for The Oncology Institute Inc .
The Oncology Institute Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Merck and Co Inc | EMEA 21.50 % |
| Pfizer Inc | United States 63.93 % |
| Bristol myers Squibb Company | United States 69.43 % |
| Aon Plc | Europe, Middle East, and Africa, Other Than United Kingdom and Ireland 14.78 % |
| Cardinal Health Inc | United States 99.35 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
The Oncology Institute Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 48 companies in The Oncology Institute Inc's industry classification, broader than the peer set above. Market cap in millions of $.The Oncology Institute Inc ranks #0 of 48 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,836, indicating a moderately concentrated market structure (see Methodology: Market Structure & Concentration).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Hca Healthcare Inc | 111,528 | 40.08 % |
| 2 | Tenet Healthcare Corp | 24,456 | 8.79 % |
| 3 | Brightspring Health Services Inc | 14,994 | 5.39 % |
| 4 | Encompass Health Corporation | 13,794 | 4.96 % |
| 5 | Davita Inc | 1,234 | 5.2% |
| 6 | Universal Health Services Inc | 1,234 | 5.2% |
| 7 | Ensign Group Inc | 1,234 | 5.2% |
| 8 | Pacs Group Inc | 1,234 | 5.2% |
| 9 | Chemed Corporation | 1,234 | 5.2% |
| 10 | Fresenius Medical Care Ag | 1,234 | 5.2% |
| 0 | The Oncology Institute Inc | 631 | 0.00 % |
Market cap and industry share for the rest of The Oncology Institute Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-08-11.
The Oncology Institute Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Healthcare Facilities industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (113 companies). See the full Healthcare Facilities industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 45.18 % | 34.25 % (avg) | +10.9 pp |
| Operating Margin | -4.44 % | industry median | -12.1 pp |
| EBITDA Margin | -3.29 % | 2.94 % (avg) | -6.2 pp |
| Capital Intensity (Capex / Revenue) | 0.62 % | 3.80 % (avg) | -3.2 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
The Oncology Institute Inc's Valuation vs Competitive Position
Valuation multiples vs the Healthcare Facilities industry average (113 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Healthcare Facilities industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 21.2x | - |
| EV / EBITDA | - | 13.9x | - |
| P/B | -25.0x | 3.1x | -28.1x |
| Return on Equity | - | industry aggregate | - |
| Return on Invested Capital | -35.41 % | 1.98 % (avg) | -37.39 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
The Oncology Institute Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2020 | 2021 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | 28.42 % | 21.33 % | 27.79 % |
| Operating Margin | - | - | -23.75 % | -15.28 % | -7.18 % |
| Return on Invested Capital | - | -19.34 % | -26.73 % | -37.24 % | -40.17 % |
| P/E | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
The Oncology Institute Inc's Strategic Group Map
The Oncology Institute Inc is shown in red; its closest peers by combined growth, margin and ROIC are labeled. See Methodology: Strategic Group Map for how this chart is built.
The Oncology Institute Inc's trailing-12-month revenue growth of 38.4% and operating margin of -4.4% compares with an average of 33.1% growth and -2.3% margin across its 8 closest peers by combined growth, margin and ROIC -- The Oncology Institute Inc sits above that peer average on growth and below it on margin.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
The Oncology Institute Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Moderate | Industry HHI of 1,836 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 0.62 % vs industry average 3.80 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on The Oncology Institute Inc's dedicated Suppliers and Customers pages, not here.
The Oncology Institute Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
The Oncology Institute Inc falls in the Medium attractiveness / Medium strength cell: Selective.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
The Oncology Institute Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+9.9% annualized vs trailing 12 months).
Weaknesses
- Operating margin 12.1 points below the industry median.
Opportunities
No rule matched.
Threats
- Industry dominated by Hca Healthcare Inc , holding 40.08 % of industry market cap.
Methodology: see Methodology: SWOT Analysis.
The Oncology Institute Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| The Oncology Institute Inc | - | 1.51 | - |
| Merck and Co Inc | 0.40 | 1.46 | 1.01 |
| Astrazeneca Plc | 0.19 | 0.94 | 0.51 |
| Pfizer Inc | 0.04 | 1.27 | 0.72 |
| Bristol myers Squibb Company | 0.48 | 1.44 | 2.12 |
| Mckesson Corporation | 0.07 | 0.88 | - |
Sign in to see all peers for The Oncology Institute Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
The Oncology Institute Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| The Oncology Institute Inc | Q2 2026 | +34.6 % | - |
| Merck and Co Inc | Q2 2026 | +5.1 % | - |
| Astrazeneca Plc | Q4 2025 | +8.6 % | +45.3 % |
| Pfizer Inc | Q3 2026 | -0.4 % | -8.7 % |
| Bristol myers Squibb Company | Q3 2026 | +6.9 % | -1.5 % |
| Mckesson Corporation | Q2 2026 | +7.7 % | +24.2 % |
| PEERS TOTAL | +8.2 % | -12.6 % |
Sign in to see all peers for The Oncology Institute Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
The Oncology Institute Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| The Oncology Institute Inc | Q2 2026 | - | -24.8 % |
| Merck and Co Inc | Q2 2026 | +23.6 % | +16.9 % |
| Astrazeneca Plc | Q4 2025 | +11.2 % | +46.0 % |
| Pfizer Inc | Q3 2026 | -3.5 % | -4.8 % |
| Bristol myers Squibb Company | Q3 2026 | +20.7 % | +7.5 % |
| Mckesson Corporation | Q2 2026 | +7.6 % | -19.6 % |
Sign in to see all peers for The Oncology Institute Inc .
The Oncology Institute Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| The Oncology Institute Inc | - | - | - |
| Merck and Co Inc | 2.42% | 3.24% | 6.59% |
| Astrazeneca Plc | 8.97% | 19.67% | 21.00% |
| Pfizer Inc | 1.98% | 2.34% | 4.62% |
| Bristol myers Squibb Company | 10.47% | 13.59% | 43.83% |
| Mckesson Corporation | 6.43% | 35.05% | - |
Sign in to see all peers for The Oncology Institute Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
The Oncology Institute Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| The Oncology Institute Inc | - | 1.09 |
| Merck and Co Inc | 118.96 | 5.47 |
| Astrazeneca Plc | 28.64 | 4.98 |
| Pfizer Inc | 41.57 | 2.64 |
| Bristol myers Squibb Company | 13.82 | 2.56 |
| Mckesson Corporation | 28.47 | 0.31 |
| PEERS AVERAGE | 32.16 | 1.31 |
Sign in to see all peers for The Oncology Institute Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.